NVAX
Price
$6.80
Change
+$0.04 (+0.59%)
Updated
Jul 3 closing price
Capitalization
1.1B
33 days until earnings call
WXIBF
Price
$3.18
Change
+$0.33 (+11.58%)
Updated
Jun 27 closing price
Capitalization
13.37B
Interact to see
Advertisement

NVAX vs WXIBF

Header iconNVAX vs WXIBF Comparison
Open Charts NVAX vs WXIBFBanner chart's image
Novavax
Price$6.80
Change+$0.04 (+0.59%)
Volume$2.29M
Capitalization1.1B
Wuxi Biologics Cayman
Price$3.18
Change+$0.33 (+11.58%)
Volume$300
Capitalization13.37B
NVAX vs WXIBF Comparison Chart in %
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WXIBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVAX vs. WXIBF commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a StrongBuy and WXIBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (NVAX: $6.80 vs. WXIBF: $3.18)
Brand notoriety: NVAX: Notable vs. WXIBF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 25% vs. WXIBF: 18%
Market capitalization -- NVAX: $1.1B vs. WXIBF: $13.37B
NVAX [@Biotechnology] is valued at $1.1B. WXIBF’s [@Biotechnology] market capitalization is $13.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileWXIBF’s FA Score has 1 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • WXIBF’s FA Score: 1 green, 4 red.
According to our system of comparison, WXIBF is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while WXIBF’s TA Score has 5 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 4 bearish.
  • WXIBF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, WXIBF is a better buy in the short-term than NVAX.

Price Growth

NVAX (@Biotechnology) experienced а +4.62% price change this week, while WXIBF (@Biotechnology) price change was +11.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

NVAX is expected to report earnings on Aug 06, 2025.

WXIBF is expected to report earnings on Apr 29, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WXIBF($13.4B) has a higher market cap than NVAX($1.1B). WXIBF has higher P/E ratio than NVAX: WXIBF (29.22) vs NVAX (2.47). WXIBF YTD gains are higher at: 46.544 vs. NVAX (-15.423). WXIBF has higher annual earnings (EBITDA): 5.5B vs. NVAX (555M). WXIBF has higher revenues than NVAX: WXIBF (17B) vs NVAX (1.22B).
NVAXWXIBFNVAX / WXIBF
Capitalization1.1B13.4B8%
EBITDA555M5.5B10%
Gain YTD-15.42346.544-33%
P/E Ratio2.4729.228%
Revenue1.22B17B7%
Total Cash731MN/A-
Total Debt229MN/A-
FUNDAMENTALS RATINGS
NVAX vs WXIBF: Fundamental Ratings
NVAX
WXIBF
OUTLOOK RATING
1..100
797
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10043
PRICE GROWTH RATING
1..100
6341
P/E GROWTH RATING
1..100
408
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WXIBF's Valuation (70) in the null industry is in the same range as NVAX (87) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

WXIBF's Profit vs Risk Rating (100) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

WXIBF's SMR Rating (43) in the null industry is somewhat better than the same rating for NVAX (100) in the Biotechnology industry. This means that WXIBF’s stock grew somewhat faster than NVAX’s over the last 12 months.

WXIBF's Price Growth Rating (41) in the null industry is in the same range as NVAX (63) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

WXIBF's P/E Growth Rating (8) in the null industry is in the same range as NVAX (40) in the Biotechnology industry. This means that WXIBF’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXWXIBF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
70%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WXIBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IETC94.841.41
+1.51%
iShares U.S. Tech Independence Fcs ETF
XMAY33.390.06
+0.19%
FT Vest US Eq Enh & Mod Buf ETF-May
FXED18.23-0.01
-0.03%
Sound Enhanced Fixed Income ETF
MBS8.62N/A
-0.05%
Angel Oak Mortgage-Backed Securities ETF
SCHR24.81-0.06
-0.24%
Schwab Intermediate-Term US Trs ETF™

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+0.59%
MRNA - NVAX
45%
Loosely correlated
+0.69%
ARCT - NVAX
43%
Loosely correlated
+1.17%
THRD - NVAX
42%
Loosely correlated
+0.18%
BNTX - NVAX
41%
Loosely correlated
+1.61%
CRSP - NVAX
39%
Loosely correlated
+0.97%
More

WXIBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, WXIBF has been loosely correlated with WXXWY. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if WXIBF jumps, then WXXWY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WXIBF
1D Price
Change %
WXIBF100%
N/A
WXXWY - WXIBF
46%
Loosely correlated
+0.08%
JAGX - WXIBF
22%
Poorly correlated
+0.39%
NVAX - WXIBF
21%
Poorly correlated
+0.59%
ELVAF - WXIBF
21%
Poorly correlated
N/A
EVAX - WXIBF
20%
Poorly correlated
-3.24%
More